

# Marina Natoli

marina.natoli@unibas.ch

+41779807593

Nationality: Italian, British

## Education

**PhD, Clinical Medicine Research (Surgery and Cancer)**

Imperial College London

**MSc, Biomedical Sciences, 2013- 2014, Award: Distinction**

University College London

**BSc, Medical Biotechnology, 2009-2013, Award: 110, summa cum laude**

Università degli Studi di Palermo

## Employment and research experience

### Postdoctoral Scientist, Universitätsspital Basel (January 2020 – present)

Prof Zippelius' Cancer Immunology Research Group

### Doctoral Researcher, Imperial College London (July 2016 – January 2020)

Prof Ghaem-Maghani's Tumour Immunology and Immunotherapy Research Group

Working on epigenetic modification of ovarian cancer immunogenicity and combination with T cell immunotherapies; combining molecular immunology and bioinformatics in translational oncology research.

### Graduate Teaching Assistant, Imperial College London (July 2016 – January 2020)

Assisting in the laboratory sessions, lecturing and supervising students at Imperial College London for the following courses: Mastering laboratory skills course, BSc Immunity and infection, BSc Medical Biosciences, MSc Immunology, MSc Molecular Biology and Pathology of Viruses, MSc Molecular Medicine, MSc Functional Omics.

### Research Assistant, Imperial College London (September 2014– July 2016)

Prof Ghaem-Maghani's Tumour Immunology and Immunotherapy Research Group

**Project co-lead**, working on mechanisms of synergy in chemo-immunotherapy combinations in ovarian cancer. Using ErbB-targeted CAR T cells in combination with carboplatin and paclitaxel in *in vitro* and *in vivo* ovarian cancer models.

### MSc Project, University College London (April 2014– September 2014)

Dr Adam Giangreco's research group in UCL Lungs for Living Research Centre

Studying the role of Cell Adhesion Molecule-1 (CADM1) loss in non-small cell lung cancer.

### BSc Project, National Research Council - Institute of Biomedicine and Molecular Immunology (Palermo, Italy) Sep 2012-Feb 2013

Dr Agata Giallongo's molecular and cellular biology research group

Using RNAi to study cell fate pathways in skeletal muscle tissues.

## Academic achievements and participation

### Publications

- **Natoli M.** et. al., *Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade*. *Cancer Immunol. Immunother.* (in press, **February 2020**).
- Wahba J/ **Natoli M.** et al., *Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer – Cancer Immunol Immunother.* **2018** Nov;67(11):1753-1765. doi: 10.1007/s00262-018-2199-8. Epub 2018 Aug 24. (Co-first authorship)
- **Natoli M** et al. *Immunomodulatory action of SGI-110 and combination with gamma-delta T cell immunotherapy in ovarian cancer*. Abstract 4567, Proceedings of the American Association for Cancer Research, Volume 59, April **2018**.
- Wahba J, **Natoli M** et al. *Synergistic immuno-chemotherapy for ovarian cancer*. July **2016**. *BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY*, Vol: 123, Pages: E6-E7, ISSN: 1470-0328

## Research work presentations

- Wahba J, **Natoli M** et al. *Determining a mechanism of synergistic immuno-chemotherapy in ovarian cancer*. July **2016**. European Journal of Cancer 61(1):S217-S218. DOI: 10.1016/S0959-8049(16)61767-7.
- 8-13 February 2015 – Banff, Canada - The Keystone Symposia - **Poster Presentation**
- 12-15 April 2015 - Brisbane, Australia - RCOG World Congress 2015 - **Poster Presentation**
- 12-13 May 2016 - Birmingham, United Kingdom - BGCS Annual Scientific Meeting - **Poster Presentation**
- 9–12 July 2016 - Manchester, United Kingdom - 24th Biennial Congress of the European Association for Cancer Research (EACR24) - **Poster Presentation**
- 12-13 May 2017 – London, UK- The Institute for Cancer Vaccines and Immunotherapy (ICVI) –Third International Symposium on Immunotherapy – **Poster and Oral presentations**
- 13 June 2017 – London, UK – Imperial College London Work in Progress Seminar Series - Immunomodulatory action of Guadecitabine and combination with gamma delta T cell immunotherapy in Ovarian Cancer - **Oral presentation**
- 24-28 June 2017 – Florence, Italy - 2nd EACR-AACR-SIC Special Conference: The Challenges of Optimising Immuno and Targeted Therapies – **Poster presentation**
- 7-11 August 2017 – Hong Kong, China – AACR Croucher Summer Course in Cancer Biology – **Poster presentation**
- 9-12 October 2017 – Barcelona, Spain – EACR conference on Defence is the Best Attack: Immuno-Oncology Breakthroughs – **Poster presentation**
- 2 November 2017 – Helsinki, Finland - 70th Annual Meeting of the Finnish Endocrine Society - Immunological profiling of ovarian tumours & immune-regulatory mechanisms in ovarian cancer – **Invited Speech**
- 14-18 April 2018 – Chicago, IL - AACR Annual Meeting – **Poster Presentation**
- 23 October 2018 – London, UK – Imperial College London Work in Progress Seminar Series - DNMTi-driven immunomodulation of ovarian cancer via induced expression of endogenous retroviruses- **Oral presentation**

## Grants, awards and recognitions

- February 2013 – **Special honourable mention** on Dissertation ‘The over-expression of microRNA miR-206 and the myogenic transcriptional factor MyoD in an in vitro model for skeletal muscle differentiation’
- April 2015 - **Singulex SMC Technology Innovation Award** for the project "Investigating the role of sPDL-1 as a diagnostic and prognostic biomarker in ovarian cancer"
- January 2016 – MRC DTP 3.5 year **PhD Studentship**
- January 2017 – MRC DTP **Colloquium Writing competition – 1<sup>st</sup> Prize**
- May 2017 – MRC Supplement Scheme – **Exceptional training opportunities funding**
- July 2017 – Imperial College Trust – **Travel Award**
- August 2017 – **EACR Meeting Bursary** (Defence is the Best Attack: Immuno-Oncology Breakthroughs)
- January 2018 – **Genesis Research Trust Grant** – Award 1804 for the project “Immunomodulatory action of Guadecitabine and combination with gd T cell immunotherapy”
- March 2018 - MRC Supplement Scheme – **Industry Training Fund**
- August 2018 – **Associate fellowship of the Higher education academy** (AFHEA)
- January 2020 - MRC Supplement Scheme – **PhD to Postdoctoral Transition Award**

## Professional memberships/licences:

Society of Biology licence to carry out regulated procedures on mice, as regulated by the Animals (Scientific Procedures) Act 1986 (UK).